Lung Cancer Chemoprevention

作者: Robert L. Keith

DOI: 10.1513/PATS.201107-038MS

关键词: OncologyCancerLung cancerDysplasiaClinical trialInternal medicineMetaplasiaBreast cancerMedicineCarcinogenesisDisease

摘要: Lung cancer is the leading cause of death in United States, and majority diagnoses are made former smokers. Although avoidance tobacco abuse smoking cessation clearly will have greatest impact on lung development, effective chemoprevention could prove to be more than treatment established, advanced-stage disease. Chemoprevention use dietary or pharmaceutical agents reverse block carcinogenic process has been successfully applied common malignancies other (including recent reports prevention breast high-risk individuals). Despite previous studies failing identify agents, our ability define highest-risk populations understanding tumor premalignant biology continue make advances. Squamous cell carcinogenesis bronchial epithelium starts with normal progresses through hyperplasia, metaplasia, dysplasia, c...

参考文章(44)
Yasushi Hoshikawa, Tracy L. Gesell, Alvin M. Malkinson, Robert L. Keith, York E. Miller, Mark W. Geraci, Heiko A. Golpon, Raphael A. Nemenoff, Bifeng Gao, Mark D. Moore, Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer Cancer Research. ,vol. 62, pp. 734- 740 ,(2002)
Alejandro Sweet-Cordero, George C. Tseng, Han You, Margaret Douglass, Bing Huey, Donna Albertson, Tyler Jacks, Comparison of gene expression and DNA copy number changes in a murine model of lung cancer. Genes, Chromosomes and Cancer. ,vol. 45, pp. 338- 348 ,(2006) , 10.1002/GCC.20296
Yvette Bren-Mattison, Vicki Van Putten, Daniel Chan, Robert Winn, Mark W Geraci, Raphael A Nemenoff, Peroxisome proliferator-activated receptor-γ (PPARγ) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC) Oncogene. ,vol. 24, pp. 1412- 1422 ,(2005) , 10.1038/SJ.ONC.1208333
Ralph Meuwissen, Sabine C Linn, R.Ilona Linnoila, John Zevenhoven, Wolter J Mooi, Anton Berns, Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model Cancer Cell. ,vol. 4, pp. 181- 189 ,(2003) , 10.1016/S1535-6108(03)00220-4
Nicholas R. Anthonisen, Melissa A. Skeans, Robert A. Wise, Jure Manfreda, Richard E. Kanner, John E. Connett, , The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality Annals of Internal Medicine. ,vol. 142, pp. 233- 239 ,(2005) , 10.7326/0003-4819-142-4-200502150-00005
Saswati Hazra, Raj K Batra, Hsin H Tai, Sherven Sharma, Xiaoyan Cui, Steven M Dubinett, None, Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Molecular Pharmacology. ,vol. 71, pp. 1715- 1720 ,(2007) , 10.1124/MOL.106.033357
Longzheng Tong, Margaret R Spitz, John J Fueger, Christopher I Amos, None, Lung carcinoma in former smokers. Cancer. ,vol. 78, pp. 1004- 1010 ,(1996) , 10.1002/(SICI)1097-0142(19960901)78:5<1004::AID-CNCR10>3.0.CO;2-6
Andre Castonguay, Nathalie Rioux, Inhibition of lung tumourigenesis by sulindac: comparison of two experimental protocols. Carcinogenesis. ,vol. 18, pp. 491- 496 ,(1997) , 10.1093/CARCIN/18.3.491